Bristol-Myers Squibb (BMY) Says CheckMate -026 Trial for Opdivo Missed Primary Endpoint
Tweet Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) announced that CheckMate -026, a trial investigating the use of Opdivo (nivolumab) as monotherapy, did ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
